Low-molecular-weight heparin in the prevention and treatment of thromboembolic disorders
- 作者：Hermes De Santis ; Evelyn R. ; Laumeister ; Betsy S. ; Bansal ; Vidhu ; Kataria ; Vandana ; Loomba ; Preeti ; et. al.
- 刊名：Disease Management and Clinical Outcomes
- 出版年：1998
- 期刊代码：80_10883371
- 类别：med
- 出版时间：September 10, 1998
- 卷：1
- 期：5
- 页码：166-174
- 文件大小：98.9 K
摘要
The efficacy of the low-molecular-weight heparins (LMWHs) in both preventing and treating thromboembolic events has been repeatedly demonstrated. Currently, there are three LMWHs available in the United States. The anticoagulation ability of the LMWHs is due to inhibition of factor Xa. The LMWHs have little to no effect on the prothrombin or partial thromboplastin times; therefore, monitoring of these traditional parameters is not warranted. The increased bioavailability of the LMWHs allows for more predictable anticoagulation at a given dose. However, there are certain patient populations (for example: pregnancy, renal failure, and obesity) which may require monitoring of anti-Factor Xa concentrations to determine anticoagulation status. Many studies have shown therapeutic benefit in comparison to unfractionated heparin, warfarin, and non-pharmacological measures (i.e., intermittent pneumatic compression, elastic stockings, and early ambulation).